67335-09-5

Basic information

• Product Name: 1-Isoquinolinecarbonitrile, 2-benzoyl-5-bromo-1,2-dihydro-
• CAS NO: 67335-09-5
• Molecular Formula: C17H11BrN2O
• Molecular Weight: 339.191
• Mol File: 67335-09-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-Isoquinolinecarbonitrile, 2-benzoyl-5-bromo-1,2-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Isoquinolinecarbonitrile, 2-benzoyl-5-bromo-1,2-dihydro-(67335-09-5)
• EPA Substance Registry System: 1-Isoquinolinecarbonitrile, 2-benzoyl-5-bromo-1,2-dihydro-(67335-09-5)

Safety Data

• Hazardous Substances Data: 67335-09-5(Hazardous Substances Data)

Usage

Type of Compound

Derivative of isoquinoline

Appearance

White to off-white powder

Solubility

Soluble in organic solvents

Potential Applications

Pharmaceutical and organic synthesis, development of new drugs and agrochemicals

Molecular Structure

Contains a benzoyl group and a bromine atom, which can impart unique reactivity and properties to the molecule

Research Status

Ongoing to explore its potential uses and properties in various fields.

Upstream product

• 34784-04-8 5-bromoisoquinoline 
• 7677-24-9 trimethylsilyl cyanide 
• 98-88-4 benzoyl chloride 
• 119-65-3 isoquinoline 

Downstream Products

• 1192830-01-5 1,1-dimethylethyl 3-(5-{5-[3-cyano-4-(3-fluoro-1-pyrrolidinyl)phenyl]-1,2,4-oxadiazol-3-yl}-1-isoquinolinyl)propanoate 
• 1192829-99-4 1,1-dimethylethyl 3-[5-(5-{3-cyano-4-[(2,2,2-trifluoroethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1-isoquinolinyl]propanoate 
• 1192829-58-5 3-(5-{5-[3-cyano-4-(3-fluoro-1-pyrrolidinyl)phenyl]-1,2,4-oxadiazol-3-yl}-1-isoquinolinyl)propanoic acid 
• 1192829-97-2 1,1-dimethylethyl 3-[5-(5-{3-chloro-4-[(2,2,2-trifluoroethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1-isoquinolinyl]propanoate 
• 1192829-98-3 1,1-dimethylethyl 3-[5-(5-{3-cyano-4-[(cyclopropylmethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1-isoquinolinyl]propanoate 
• 1192829-57-4 3-[5-(5-{3-cyano-4-[(2,2,2-trifluoroethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1-isoquinolinyl]propanoic acid 
• 1192829-95-0 1,1-dimethylethyl 3-[5-(5-{3-chloro-4-[(cyclopropylmethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1-isoquinolinyl]propanoate 
• 1192829-54-1 3-[5-(5-{3-cyano-4-[(cyclopropylmethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1-isoquinolinyl]propanoic acid 
• 1192829-96-1 1,1-dimethylethyl 3-[5-(5-{3-chloro-4-[(difluoromethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1-isoquinolinyl]propanoate 
• 1192830-02-6 1,1-dimethylethyl 3-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1-isoquinolinyl]propanoate 
• 1192829-51-8 3-[5-(5-{3-chloro-4-[(cyclopropylmethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1-isoquinolinyl]propanoic acid 
• 1192830-00-4 1,1-dimethylethyl 3-{5-[5-(3-cyano-4-fluorophenyl)-1,2,4-oxadiazol-3-yl]-1-isoquinolinyl}propanoate 
• 1192829-52-9 3-[5-(5-{3-chloro-4-[(difluoromethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1-isoquinolinyl]propanoic acid 
• 1192829-30-3 3-[5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1-isoquinolinyl]-1-propanol 

Relevant articles and documents

COMPOUNDS

The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

Synthesis and radioligand binding studies of C-5- and C-8-substituted 1-(3,4-dimethoxybenzyl)-2,2-dimethyl-1,2,3,4-tetrahydroisoquinoliniums as SK channel blockers related to N-methyl-laudanosine and N-methyl-noscapine

The synthesis and the 125I-apamin binding studies of original C-5- and C-8-substituted 1-(3,4-dimethoxy-benzyl)-2,2-dimethyl-1,2,3,4- tetrahydroisoquinoliniums and 1-(3,4-dimethoxy-benzyl)-6,6-dimethyl-4,5,6,7- tetrahydrothieno[2,3-c]pyridiniums were performed in order to find a reversible and selective SK channel blocker structurally related to N-methyl-laudanosine and N-methyl-noscapine. A bulky alkyl substituent in the C-8 position of the tetrahydroisoquinoline produces a clear increase in the affinity for the apamin sensitive binding sites. The presence of an electron-withdrawing group in the C-5 and C-8 positions is not a suitable substitution for the affinity of drugs structurally related to N-methyl-laudanosine. Thiophenic analogues and 8-methoxy derivatives possess a poor affinity for the apamin sensitive binding sites. Electrophysiological studies performed with the most effective compound showed a blockade of the apamin sensitive afterhyperpolarization in rat dopaminergic neurons.